302 related articles for article (PubMed ID: 38602556)
1. Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review.
Tang L; Xu H; Wu T; Wu W; Lu Y; Gu J; Wang X; Zhou M; Chen Q; Sun X; Cai H
Discov Oncol; 2024 Apr; 15(1):111. PubMed ID: 38602556
[TBL] [Abstract][Full Text] [Related]
2. Strategies for Overcoming Immune Evasion in Bladder Cancer.
Shin J; Park JW; Kim SY; Lee JH; Choi WS; Kim HS
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542078
[TBL] [Abstract][Full Text] [Related]
3. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
4. Single-cell sequencing technologies in bladder cancer research: Applications and challenges.
Lyu T; Lin Y; Wu K; Cao Z; Zhang Q; Zheng J
Front Genet; 2022; 13():1027909. PubMed ID: 36338973
[TBL] [Abstract][Full Text] [Related]
5. Endoplasmic Reticulum Stress and Tumor Microenvironment in Bladder Cancer: The Missing Link.
Nie Z; Chen M; Wen X; Gao Y; Huang D; Cao H; Peng Y; Guo N; Ni J; Zhang S
Front Cell Dev Biol; 2021; 9():683940. PubMed ID: 34136492
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint blockade therapy for bladder cancer treatment.
Kim J
Investig Clin Urol; 2016 Jun; 57 Suppl 1(Suppl 1):S98-S105. PubMed ID: 27326412
[TBL] [Abstract][Full Text] [Related]
7. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Glaviano A; Foo ASC; Lam HY; Yap KCH; Jacot W; Jones RH; Eng H; Nair MG; Makvandi P; Geoerger B; Kulke MH; Baird RD; Prabhu JS; Carbone D; Pecoraro C; Teh DBL; Sethi G; Cavalieri V; Lin KH; Javidi-Sharifi NR; Toska E; Davids MS; Brown JR; Diana P; Stebbing J; Fruman DA; Kumar AP
Mol Cancer; 2023 Aug; 22(1):138. PubMed ID: 37596643
[TBL] [Abstract][Full Text] [Related]
8. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
Ascione CM; Napolitano F; Esposito D; Servetto A; Belli S; Santaniello A; Scagliarini S; Crocetto F; Bianco R; Formisano L
Cancer Treat Rev; 2023 Apr; 115():102530. PubMed ID: 36898352
[TBL] [Abstract][Full Text] [Related]
9. In brief: Adstiladrin - a gene therapy for bladder cancer.
Med Lett Drugs Ther; 2023 Mar; 65(1671):e40-e41. PubMed ID: 36877284
[No Abstract] [Full Text] [Related]
10. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
Hahn NM; O'Donnell MA; Efstathiou JA; Zahurak M; Rosner GL; Smith J; Kates MR; Bivalacqua TJ; Tran PT; Song DY; Baras AS; Matoso A; Choi W; Smith KN; Pardoll DM; Marchionni L; McGuire B; Grace Phelan M; Johnson BA; O'Neal T; McConkey DJ; Rose TL; Bjurlin M; Lim EA; Drake CG; McKiernan JM; Deutsch I; Anderson CB; Lamm DL; Geynisman DM; Plimack ER; Hallman MA; Horwitz EM; Al-Saleem E; Chen DYT; Greenberg RE; Kutikov A; Guo G; Masterson TA; Adra N; Kaimakliotis HZ
Eur Urol; 2023 Jun; 83(6):486-494. PubMed ID: 36717286
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan.
Fontes MS; Vargas Pivato de Almeida D; Cavalin C; Tagawa ST
Onco Targets Ther; 2022; 15():1531-1542. PubMed ID: 36575731
[TBL] [Abstract][Full Text] [Related]
12. The Combination of Inflammatory Biomarkers as Prognostic Indicator in Salivary Gland Malignancy.
Abbate V; Barone S; Troise S; Laface C; Bonavolontà P; Pacella D; Salzano G; Iaconetta G; Califano L; Dell'Aversana Orabona G
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497416
[TBL] [Abstract][Full Text] [Related]
13. Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets.
di Meo NA; Lasorsa F; Rutigliano M; Loizzo D; Ferro M; Stella A; Bizzoca C; Vincenti L; Pandolfo SD; Autorino R; Crocetto F; Montanari E; Spilotros M; Battaglia M; Ditonno P; Lucarelli G
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430837
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
